Literature DB >> 8228580

Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.

J C Gris1, S Neveu, P Mares, C Biron, B Hedon, J F Schved.   

Abstract

The fibrinolytic response to a venous occlusion test was evaluated in 116 consecutive patients who had each had early recurrent miscarriages of unknown origin. A normal response to venous occlusion was defined from the statistical analysis of data obtained in a matched group of 90 women with no past abortion. Seventy-four patients had at least one abnormal fibrinolysis-related test, whereas no member of the control group had any (p < 10(-6)). Fifty-six of the patients had a stasis-induced shortening of the euglobulin clot lysis time that was less than normal (median decrement 3.5% [normal > or = 28%] [p < 10(-6)]). In this subgroup, 17 women also had a poor tissue-type plasminogen activator (tPA) response (median increment 18% [normal > or = 34%] [p < 0.001]). Twenty-one of the 56 had high plasma levels of type 1 plasminogen activator inactivator (PAI-1) as well as a high PAI activity level (p < 0.001 for comparison with normal controls). Sixteen patients had both abnormalities (tPA response blunted and high PAI values). When retested in the same patients, the patterns persisted over time. Nine other habitual aborters had abnormally high type 2 plasminogen activator inhibitor plasma levels (> 4.2 ng/ml). Six other patients had a poor urokinase-type plasminogen activator reactivity to venous occlusion (post-stasis levels lower than 0.18 ng/ml). Thus activators and inhibitors of the fibrinolytic system are frequently abnormal in primary habitual aborters. The current pathogeneses of high PAI-1 concentrations and of impaired tPA reactivity to venous occlusion were not found in these patients. The role of the fibrinolytic components in trophoblast invasiveness has been suspected in animals, and an impaired plasmin-dependent proteolysis in women might favor recurrent abortion by promoting fibrin deposition in early placental circulation or by limiting trophoblast development, or both.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228580

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  6 in total

1.  Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.

Authors:  C Bu; C Zhang; Z Li; L Gao; Z Xie; G Cai
Journal:  Clin Exp Immunol       Date:  2007-04-11       Impact factor: 4.330

2.  The comparison of insulin resistance frequency in patients with recurrent early pregnancy loss to normal individuals.

Authors:  Kotanaie Maryam; Zinatossadat Bouzari; Zahra Basirat; Mehrdad Kashifard; Mahtab Zeinal Zadeh
Journal:  BMC Res Notes       Date:  2012-03-09

Review 3.  Evidence-based management of recurrent miscarriages.

Authors:  Yadava B Jeve; William Davies
Journal:  J Hum Reprod Sci       Date:  2014-07

Review 4.  Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.

Authors:  Yao Ye; Aurelia Vattai; Xi Zhang; Junyan Zhu; Christian J Thaler; Sven Mahner; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

5.  Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses.

Authors:  Yao Ye; Aurelia Vattai; Nina Ditsch; Christina Kuhn; Martina Rahmeh; Sven Mahner; Myriam Ripphahn; Roland Immler; Markus Sperandio; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Endocr Connect       Date:  2018-04-26       Impact factor: 3.335

6.  Association of Polymorphisms in Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), and Renin (REN) with Recurrent Pregnancy Loss in Korean Women.

Authors:  Hee Young Cho; Han Sung Park; Eun Hee Ahn; Eun Ju Ko; Hyeon Woo Park; Young Ran Kim; Ji Hyang Kim; Woo Sik Lee; Nam Keun Kim
Journal:  J Pers Med       Date:  2021-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.